Five Prime Therapeutics Inc  

(Public, NASDAQ:FPRX)   Watch this stock  
Find more results for FPRX
46.03
-0.60 (-1.29%)
After Hours: 46.03 0.00 (0.00%)
Oct 18, 4:35PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 45.01 - 46.85
52 week 25.97 - 60.98
Open 46.79
Vol / Avg. 387,686.00/418,869.00
Mkt cap 1.33B
P/E     -
Div/yield     -
EPS -4.24
Shares 28.90M
Beta 4.18
Inst. own 86%
Sep 28, 2017
Five Prime Therapeutics Inc at Leerink Partners Roundtable Series: Rare Disease & Immuno-Oncology
Sep 6, 2017
Five Prime Therapeutics, Inc. Presents at Citi's 12th Annual Biotech Conference, Sep-06-2017 03:00 PM
Sep 6, 2017
Inovio Pharmaceuticals Inc, Aduro Biotech Inc, Five Prime Therapeutics Inc & Mirati Therapeutics Inc at Citi Biotech Conference - Panel - Webcast
Aug 8, 2017
Q2 2017 Five Prime Therapeutics Inc Earnings Call - Webcast
Aug 3, 2017
Five Prime Therapeutics Inc at Wells Fargo San Francisco Biotech Corporate Access Day
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -566.17% -214.06%
Operating margin -553.38% -323.26%
EBITD margin - -317.58%
Return on average assets -45.02% -13.18%
Return on average equity -52.22% -15.93%
Employees 195 -
CDP Score - -

Address

2 Corporate Dr
SOUTH SAN FRANCISCO, CA 94080-7047
United States - Map
+1-415-3655600 (Phone)
+1-415-3655601 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Five Prime Therapeutics, Inc. is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company's product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma. Its preclinical programs include FPA150, FPA154 and FPT155.

Officers and directors

Lewis T. Williams M.D. Ph.D. Chairman of the Board, President, Chief Executive Officer
Age: 67
Bio & Compensation  - Reuters
Marc L. Belsky Chief Financial Officer, Senior Vice President
Age: 61
Bio & Compensation  - Reuters
Aron Marc Knickerbocker MBA Chief Operating Officer, Director
Age: 47
Bio & Compensation  - Reuters
Kevin Baker Ph.D. Senior Vice President, Development Sciences
Age: 56
Bio & Compensation  - Reuters
Helen Louise Collins M.D. Senior Vice President and Chief Medical Officer
Age: 54
Bio & Compensation  - Reuters
Francis Willard Sarena J.D. Chief Strategy Officer and Secretary
Age: 46
Bio & Compensation  - Reuters
Mark D. McDade Lead Independent Director
Age: 61
Bio & Compensation  - Reuters
Garry Nicholson Director
Bio & Compensation  - Reuters
Franklin M. Berger Independent Director
Age: 67
Bio & Compensation  - Reuters
Fred E. Cohen Ph.D. M.D. Independent Director
Age: 60
Bio & Compensation  - Reuters